Nventa announces positive HspE7 data from NCI-sponsored clinical trial in HIV-positive patients
First Clinical Evidence that HspE7 May Have Activity in Immunocompromised Patients
19-Jun-2006 -
Nventa Biopharmaceuticals Corporation announced results, recently published in the journal AIDS, from a clinical trial to test HspE7, an investigational therapeutic vaccine for human papillomavirus (HPV)-related diseases, on patients with high-grade anal intraepithelial neoplasia (AIN), or ...
AIDS
clinical trials
diseases
+2